Cargando…
Long-Lasting Immune Responses 4 Years after GAD-Alum Treatment in Children with Type 1 Diabetes
A phase II clinical trial with glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) has shown efficacy in preserving residual insulin secretion in children and adolescents with recent-onset type 1 diabetes (T1D). We have performed a 4-year follow-up study of 59 of the...
Autores principales: | Axelsson, Stina, Chéramy, Mikael, Hjorth, Maria, Pihl, Mikael, Åkerman, Linda, Martinuzzi, Emanuela, Mallone, Roberto, Ludvigsson, Johnny, Casas, Rosaura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236224/ https://www.ncbi.nlm.nih.gov/pubmed/22174945 http://dx.doi.org/10.1371/journal.pone.0029008 |
Ejemplares similares
-
Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial
por: Axelsson, Stina, et al.
Publicado: (2013) -
Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD(65)-induced immune response
por: Tavira, Beatriz, et al.
Publicado: (2017) -
Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes
por: Barcenilla, Hugo, et al.
Publicado: (2022) -
Mass Cytometry Identifies Distinct Subsets of Regulatory T Cells and Natural Killer Cells Associated With High Risk for Type 1 Diabetes
por: Barcenilla, Hugo, et al.
Publicado: (2019) -
Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)
por: Casas, Rosaura, et al.
Publicado: (2022)